ITGAX and non-small cell lung carcinoma: ITGAL, ITGAX, the combination of ITGAL-ITGAX-TMEM119 (IIT), and two multigene panels (taxifolin signature/TxflSig and TxflSig1) all effectively predicted the response of NSCLC to anti-PD1-based ICB treatment, which outperformed CD274 (PD-L1)-based prediction.